A condition in which a single non-encephalopathic demyelinatingThe process in which the protective coating of nerve tissue (i.e. myelin) becomes damaged or breaks down, causing nerve impulses to slow or halt that results in neurological problems. attack results in damage and neurological symptoms based onInflammation of the optic nerve that may be classified as unilateral (affecting one eye) or bilateral (affecting both eyes) that may result in vision changes, vision loss, and/or pain with eye movement. the location of the brain that became damaged. In the case of multiple sclerosis (MS)An autoimmune disease that attacks healthy cells in the myelin, the protective sheath that surrounds nerves in the central nervous system (CNS) leading to neurological symptoms originating from the brain, spinal cord, and/or optic nerve., if the attack meets criteria for MSAn autoimmune disease that attacks healthy cells in the myelin, the protective sheath that surrounds nerves in the central nervous system (CNS) leading to neurological symptoms originating from the brain, spinal cord, and/or optic nerve. by McDonald criteria, then it is determined to be MSAn autoimmune disease that attacks healthy cells in the myelin, the protective sheath that surrounds nerves in the central nervous system (CNS) leading to neurological symptoms originating from the brain, spinal cord, and/or optic nerve.. If it does not meet this MSAn autoimmune disease that attacks healthy cells in the myelin, the protective sheath that surrounds nerves in the central nervous system (CNS) leading to neurological symptoms originating from the brain, spinal cord, and/or optic nerve. criteria, then it remains CIS. However, many MOGADOften referred to as MOGAD, Anti-MOG, MOG Ab+, MOG Antibody Disease, MOG Associated Antibody Disease, MOG positive disease patients with their first attack could technically meet criteria for MSAn autoimmune disease that attacks healthy cells in the myelin, the protective sheath that surrounds nerves in the central nervous system (CNS) leading to neurological symptoms originating from the brain, spinal cord, and/or optic nerve., but a trained neuroimmunologist would generally know the difference.
Clinically Isolated Syndrome (CIS)
Related Posts
The MOG Project Applauds Results from the Hoffmann-La Roche & Genentech Clinical Trial
Results point to Enspryng® (satralizumab) as effective in blocking IL-6 receptor and MOGAD-related inflammationA process of the immune system that involves chemicals released by immune cells (i.e. white blood cells) inducing localized heat, swelling, redness, and pain to an area that occurs when tissue becomes damaged or infected from a pathogen, and usually results in the desctruction and removal of the pathogen and/or healing to the tissue. In the case of myelin oligodendrocyte glycoprotein antibody disease (MOGAD), inflammation is the result of the incorrect targeting of the myelin oligodendrocyte glycoprotein (MOG) by the immune system, resulting in damage to myelin sheaths. Washington, DC – (April 21, 2026) The MOGA type of protein involved in cell adhesion. Present throughout myelin sheaths. Project is thrilled
The MOG Project Featured by Johns Hopkins Medicine
The MOGA type of protein involved in cell adhesion. Present throughout myelin sheaths. Project is honored to be featured by Johns Hopkins Medicine in a recent article highlighting advances in understanding myelin oligodendrocyte glycoprotein antibody diseaseOften referred to as MOGAD, Anti-MOG, MOG Ab+, MOG Antibody Disease, MOG Associated Antibody Disease, MOG positive disease
The MOG Project Awards 2025 Research Grants
The MOG Project’s Research for Rare program has awarded our 2025 MOGADOften referred to as MOGAD, Anti-MOG, MOG Ab+, MOG Antibody Disease, MOG Associated Antibody Disease, MOG positive disease global research grants: the Apollo Grant and the Accelerator Grant. These grants are
